logo
Proof That Adult Brains Make New Neurons Settles Scientific Controversy

Proof That Adult Brains Make New Neurons Settles Scientific Controversy

Yahoo2 days ago
For at least six decades, neuroscientists have been arguing over a big, foundational question: Do adult brains make new neurons? This process of 'neurogenesis' had been shown in other adult animals, but its evidence in humans was circumstantial—until now. Using a new technique, scientists have found newly formed neurons in the brains of adults as old as age 78—and, for the first time, have identified the other brain cells that birthed them.
The results, published on Thursday in Science, are the first signs that cells with the capacity to turn into neurons, called neural precursor cells, exist in adult human brains. 'Now we have very strong evidence that the whole process is there in humans, from the precursor cells to the immature neurons,' says Gerd Kempermann, a neurobiologist at the Dresden University of Technology, who was not involved in the study.
Throughout gestation, our brain churns out new neurons until it reaches the 100 billion we start life with, and that count declines as we age. As early as 1962, studies in rats had shown that neurogenesis continued throughout the animals' life. Others found that young neurons existed in adult human brains. But it was unclear whether these 'immature' neurons were truly new—or whether humans just start life with a collection of them, after which they slowly develop during adulthood.
[Sign up for Today in Science, a free daily newsletter]
One thing was clear from these studies: if adult neurogenesis happened anywhere, it was in the hippocampus, a deep-brain structure known for its role in memory processing and storage. But even in the human hippocampus, neuroscientists had not yet found the precursor cells that divide and develop to turn into new neurons.
Researchers at the Karolinska Institute in Sweden had previously found immature neurons in the human brain. Marta Paterlini, a neuroscientist at the institute, and her colleagues, set out to pin down how those neurons came to be. Paterlini and her team took advantage of a new combination of techniques to examine immature neurons and neural precursor cells in the hippocampi of six young children, whose brain had been donated to science upon their death. From more than 100,000 cells, the researchers sequenced RNA—bits of genetic information used to carry out actions within each cell. These markers come together to form a sort of molecular fingerprint that can be used to predict a cell's stage of life. 'It's not a matter of one marker defining active neurogenesis; it's the combination of many markers,' says Paterlini, who is co-lead author of the new study.
After identifying these markers in young brains, the team then searched for those same signatures in 19 postmortem brains ranging from 13 to 78 years old. All of the brains contained immature neurons except one. The researchers also found neural precursor cells in each of the child brains and in 12 of the 19 adolescent and adult brains.
Two adults stood out for having many more neural precursor cells and immature neurons than the rest. The younger of these two people had lived with epilepsy, which could potentially connect to the apparent abundance of neurogenesis. In mice, higher levels of neurogenesis can cause seizures, though the connection to epilepsy in humans is still unclear.
The team suspects that neurogenesis happens in other parts of the adult brain, too. In mice, new neurons are regularly made in the olfactory bulb (a structure that processes smells) as well—but the same hasn't been shown in humans. Paterlini plans to investigate whether adult neurogenesis might happen there or elsewhere in the brain.
Some research in mice suggests that disrupted neurogenesis is linked to Alzheimer's disease and depression. Learning more about how neurogenesis happens—and whether the process can be altered—could prove helpful for understanding a range of disorders and diseases, says the study's co-lead author Ionut Dumitru, a neuroscientist at the Karolinska Institute.
With the question of adult neurogenesis resolved, scientists can begin learning more about what neurogenesis does in the brain and how it affects various disorders. 'This is an important paper because it should finally put this all to rest,' Kempermann says. 'And we can now concentrate on the question: How do these cells in the human contribute to brain function?'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bobby Jenks, former White Sox closer and World Series champion, dies at 44
Bobby Jenks, former White Sox closer and World Series champion, dies at 44

Yahoo

time2 hours ago

  • Yahoo

Bobby Jenks, former White Sox closer and World Series champion, dies at 44

Bobby Jenks pitched six of his seven MLB seasons with the Chicago White Sox, helping the franchise win the 2005 World Series. (Photo by) Former Chicago White Sox closer Bobby Jenks died Friday after a battle with Stage 4 adenocarcinoma, a form of stomach cancer. Jenks was 44 years old. The two-time All-Star and 2005 World Series champion revealed his condition during a February 2025 interview with from a hospital bed in Portugal, where he moved to be closer to his wife's family. Jenks spent six of his seven MLB seasons with the White Sox. He posted back-to-back 40-save seasons in 2006 and 2007 and compiled 86 saves over his final three seasons in Chicago, but is most famous on the South Side for closing out the Fall Classic in 2005, with a future pope in attendance for Game 1. Advertisement During the 2007 season, Jenks retired 47 consecutive batters. He spent the 2011 season, his last in MLB, with the Boston Red Sox. In May 2021, Jenks began working as the pitching coach for the minor-league Grand Junction Rockies. The next season, he was promoted to manager and won the league's Manager of the Year award after helping the team win a championship. Jenks spent the 2023 season as the Princeton WhistlePigs' pitching coach before he returned to managing with the Windy City ThunderBolts later that year. A father of six, Jenks and his wife, Eleni, moved to Portugal in October 2024. Not long after they relocated, he was diagnosed with deep vein thrombosis in his right calf and later dealt with multiple blood clots in his lungs. Early in 2025, he noticed that his energy level was decreasing, and after testing at a local hospital, it was discovered that a tumor had formed in his chest. Advertisement Jenks told that the tumor spread into his stomach lining, his bones, his lower back and his hips. As Jenks was dealing with his health battle, his family was affected by the Palisades fire, which caused them to lose their home and personal belongings, except for his 2005 World Series ring. 'I've got one suitcase left to my name,' Jenks said. 'It's all gone. Everything else I've ever done. I have everything, first to first. All those things are irreplaceable.'

Night Sky: How noctilucent clouds are made and Wales' space progress
Night Sky: How noctilucent clouds are made and Wales' space progress

Yahoo

time3 hours ago

  • Yahoo

Night Sky: How noctilucent clouds are made and Wales' space progress

This week saw a wonderful display of noctilucent clouds across the region as last Sunday evening's skies took on a dramatic and eerie appearance. Nick Edwards managed to capture the event over Newport, as the sun's rays reaching out from far below the horizon lit up tiny frozen water droplets high up in the Earth's atmosphere, creating the shimmering effect of wispy white clouds tinged with blue. Taken from the Latin for 'night-shining', we can expect further activity throughout the summer. We have a full moon on Thursday, July 10. This particular full moon is often referred to as a 'Buck Moon' because of the emergence of antlers on a deer buck's forehead during this part of the season. In Celtic folklore, terms such as 'Mead' or 'Herb' Moon can be found, with the Anglo-Saxons referring to it as a 'Hay Moon.' Space news and the proposed cuts to NASA's budget by the Trump administration will more than likely impact Europe's ExoMars rover mission which is already behind schedule. With the aim of placing a rover to explore the surface of Mars, it would seem the European Space Agency, (ESA), may have to go it alone. Recently, the Snowdonia Space Centre opened its Space Test and Training Centre, (STTC), with a day of demonstrations including rocket launches and the upward despatching of a high-altitude balloon. In a move to stay competitive with the rest of the UK and indeed Europe, the day signified Wales' intent to be at the forefront of enabling those interested in having their high-tech payloads delivered into space via rockets. It's a bold and innovative concept which is slowly gathering momentum but for those who lived during a Wales that was sustained by the coal industry and in more recent times the steel industry, a stark reminder that the shift in economic focus now lies firmly with the likes of such technology as 'microgravity manufacturing.' Attended by Rebecca Evans, MS, Welsh Government cabinet secretary for economy, energy, and planning, the new centre has received £820,000 of funding from the UK Space Agency with Matt Archer, its launch director, also in attendance. All told, with other financial contributions, £1.3 million has been invested with a view to boost the local economy and employment opportunities. With six other such Spaceports at sites including Argyll in western Scotland and Newquay in Cornwall, there has to be an exercise in caution following the announcement last week that the SaxaVord Spaceport in Lamba Ness, Shetlands Islands, (which appears to be further down the operational line than others), has delayed its first satellite launch from 2025 to 2026. Finally this week, the Earth's rotation during July and August is set to speed up with Wednesday, July 9, expected to be 1.30 milliseconds shorter than the usual length of a day. The speeding up over the two months is down to several factors, including sea levels, bucking the trend that overall rotation of the Earth is slowly down. Send your astrophotography pictures to: thenightsky@

Smoking Cessation Aid Cytisinicline Could Soon Get FDA Approval
Smoking Cessation Aid Cytisinicline Could Soon Get FDA Approval

Forbes

time4 hours ago

  • Forbes

Smoking Cessation Aid Cytisinicline Could Soon Get FDA Approval

There are multiple smoking cessation products on the market. But there hasn't been a new approval of ... More a pharmacotherapy without nicotine in nearly 20 years. This could change soon, as cytisinicline was submitted to the FDA for approval on June 26, 2025. More than two-thirds of American smokers say they want to quit. However, besides nicotine replacement therapies, there are at present only two smoking cessation drugs without nicotine that are authorized for marketing by the Food and Drug Administration. This could change soon, as the pharmaceutical firm Achieve Life Sciences submitted to the FDA a new drug application last week for its prescription medicine, cytisinicline, also known as cytisine. The agency will review the medication's efficacy, safety, and tolerability profile based on evidence from two large, placebo-controlled Phase 3 clinical trials. The substance is a naturally occurring plant-based alkaloid that selectively binds to nicotinic receptors in the brain. In turn, this can help alleviate nicotine cravings and reduce withdrawal symptoms, among smokers of combustible cigarettes as well as e-cigarettes (vaping). Cytisinicline has been used as a smoking cessation product for decades in some Central and Eastern European countries. It was approved by the British Medicines and Healthcare products Regulatory Agency in March 2019, though only available commercially in the United Kingdom since January 2024. Cytisinicline hasn't yet been approved by the European Medicines Agency. The Journal of the American Medical Association Internal Medicine published results from one of two Phase 3 trials evaluating cytisinicline for smoking cessation. The authors' conclusions reaffirmed cytisinicline's efficacy and tolerability for smoking cessation in adult smokers at both 6- and 12-week treatment durations, including reduction in nicotine cravings and extended cessation benefits through 24 weeks. Additionally, a study published in 2024 suggested cytisinicline could be effective for e-cigarette cessation. Owing to its mechanism of action as a way to reduce nicotine dependence, it's possible that cytisinicline could be beneficial for individuals using nicotine pouches who wish to stop, though this hasn't yet been examined specifically. Based on a technology assessment of the benefits and costs of cytisinicline, the British cost-effectiveness watchdog, the National Institute for Health and Care Excellence, recommended earlier this year adding the drug to the National Health Service as a treatment option for smoking cessation. And this week, the American Institute for Clinical and Economic Review announced it is conducting an evidence review to assess the clinical effectiveness of cytisinicline together with behavior support. The evaluation will include comparisons with other existing smoking cessation products. Smoking is the leading cause of preventable death in the U.S. Cigarette smoking is responsible for more than 480,000 deaths annually in the U.S. The major causes of death associated with smoking include cardiovascular diseases such as strokes and heart attacks; cancers, among which lung, pancreatic, esophageal, bladder, colorectal and renal; and pulmonary conditions such as chronic obstructive lung disease, pneumonia and bronchitis. Last October, the FDA and the National Institutes of Health convened a public meeting to address the urgency for developing novel smoking cessation products to assist individuals of all ages, including underserved and vulnerable populations, to stop smoking. There is unmet need in this space, reflected in the fact that of the 15 million who tried to quit smoking in 2022, five in six failed, according to STAT News. Experts cite a lack of sufficiently effective smoking cessation drugs. Should cytisinicline become available in the U.S. it could represent an important option for those who wish to quit their nicotine habit. At the same time, it will continue to be critical for healthcare providers and public health authorities to raise awareness around the importance of smoking cessation and prevention, provide behavior support (counseling) and offer treatment alternatives people can use to quit. The U.S. has made real progress since the 1960s in reducing cigarette smoking, mainly through effective public health campaigns. Yet there's still a lot more work to do as roughly 29 million adults smoke combustible cigarettes and approximately 17 million use e-cigarettes. But under the Trump administration the Department of Health and Human Services has cut funding for smoking cessation and prevention programs, as well as eliminated the Centers for Disease Control and Prevention's Office on Smoking and Health. While the CDC says it will continue to provide resources for those who wish to quit smoking while conducting ongoing surveillance, experts warn that cuts in services could limit access, which could then result in a resurgence in smoking rates.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store